Stereotactic Ablative Radiotherapy in the Treatment of Early-Stage Lung Cancer-A Done Deal?

被引：7

作者：

Gulstene, S. ^{[1
]}

Ruwanpura, T. ^{[2
]}

Palma, D. ^{[1
]}

Joseph, N. ^{[3
]}

机构：

[1] London Hlth Sci Ctr, Dept Radiat Oncol, London, ON, Canada

[2] Christie NHS Fdn Trust, Manchester, England

[3] Minist Hlth, Colombo, Sri Lanka

来源：

CLINICAL ONCOLOGY | 2022年 / 34卷 / 11期

关键词：

Early -stage lung cancer; lung cancer; non -small cell lung cancer; NSCLC; SABR; SBRT; BODY RADIATION-THERAPY; TUMORS; SABR; PNEUMONITIS; DISEASE; SBRT; VALIDATION; RECURRENCE; PREDICTION; EXPERIENCE;

D O I：

10.1016/j.clon.2022.08.027

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Stereotactic ablative radiotherapy (SABR) is an important curative-intent treatment option for early-stage non-small cell lung cancer. It offers good cancer control without invasive surgery and has become the standard of care for medically inoperable patients. The literature on SABR for early-stage non-small cell lung cancer is substantial and continues to grow. However, there remain areas of controversy where data are limited -notably the use of SABR in medically operable patients. Other areas of some debate include the treatment of central/ultra-central and large (>5 cm) lesions, as well as treatment with co-existing interstitial lung disease. This review article provides an overview of the current literature together with a discussion of future directions.(c) 2022 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.

引用

页码：733 / 740

页数：8

共 62 条

[1]

[Anonymous], 2016, VET AFF LUNG CANC SU

[2]

[Anonymous], 2019, DURV VS PLAC STER BO

[3] Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC [J].

Antonia, S. J. ;

Villegas, A. ;

Daniel, D. ;

Vicente, D. ;

Murakami, S. ;

Hui, R. ;

Kurata, T. ;

Chiappori, A. ;

Lee, K. H. ;

de Wit, M. ;

Cho, B. C. ;

Bourhaba, M. ;

Quantin, X. ;

Tokito, T. ;

Mekhail, T. ;

Planchard, D. ;

Kim, Y. -C. ;

Karapetis, C. S. ;

Hiret, S. ;

Ostoros, G. ;

Kubota, K. ;

Gray, J. E. ;

Paz-Ares, L. ;

Carpeno, J. de Castro ;

Faivre-Finn, C. ;

Reck, M. ;

Vansteenkiste, J. ;

Spigel, D. R. ;

Wadsworth, C. ;

Melillo, G. ;

Taboada, M. ;

Dennis, P. A. ;

Ozguroglu, M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (24) :2342-2350

[4] Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial [J].

Ball, David ;

Mai, G. Tao ;

Vinod, Shalini ;

Babington, Scott ;

Ruben, Jeremy ;

Kron, Tomas ;

Chesson, Brent ;

Herschtal, Alan ;

Vanevski, Marijana ;

Rezo, Angela ;

Elder, Christine ;

Skala, Marketa ;

Wirth, Andrew ;

Wheeler, Greg ;

Lim, Adeline ;

Shaw, Mark ;

Schofield, Penelope ;

Irving, Louis ;

Solomon, Benjamin .

LANCET ONCOLOGY, 2019, 20 (04) :494-503

[5] A DOSE-VOLUME ANALYSIS OF RADIATION PNEUMONITIS IN NON-SMALL CELL LUNG CANCER PATIENTS TREATED WITH STEREOTACTIC BODY RADIATION THERAPY [J].

Barriger, R. Bryan ;

Forquer, Jeffrey A. ;

Brabham, Jeffrey G. ;

Andolino, David L. ;

Shapiro, Ronald H. ;

Henderson, Mark A. ;

Johnstone, Peter A. S. ;

Fakiris, Achilles J. .

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 82 (01) :457-462

[6] Stereotactic body radiation therapy for early-stage non-small-cell lung cancer in octogenarians and older: an alternative treatment [J].

Bei, Yanping ;

Murakami, Naoya ;

Nakayama, Yuko ;

Okuma, Kae ;

Kashihara, Tairo ;

Raturi, Vijay Parshuram ;

Okamoto, Hiroyuki ;

Takahashi, Kana ;

Inaba, Koji ;

Igaki, Hiroshi ;

Itami, Jun .

JOURNAL OF RADIATION RESEARCH, 2020, 61 (04) :586-593

[7] Empiric Radiotherapy for Lung Cancer Collaborative Group multi-institutional evidence-based guidelines for the use of empiric stereotactic body radiation therapy for non-small cell lung cancer without pathologic confirmation [J].

Berman, Abigail T. ;

Jabbour, Sahna K. ;

Vachani, Anil ;

Robinson, Cliff ;

Choi, J. Isabelle ;

Mohindra, Pranshu ;

Rengan, Ramesh ;

Bradley, Jeffrey ;

Simone, Charles B., II .

TRANSLATIONAL LUNG CANCER RESEARCH, 2019, 8 (01) :5-14

[8] Safety and Efficacy of a Five-Fraction Stereotactic Body Radiotherapy Schedule for Centrally Located Non-Small-Cell Lung Cancer: NRG Oncology/RTOG 0813 Trial [J].

Bezjak, Andrea ;

Paulus, Rebecca ;

Gaspar, Laurie E. ;

Timmerman, Robert D. ;

Straube, William L. ;

Ryan, William F. ;

Garces, Yolanda I. ;

Pu, Anthony T. ;

Singh, Anurag K. ;

Videtic, Gregory M. ;

McGarry, Ronald C. ;

Iyengar, Puneeth ;

Pantarotto, Jason R. ;

Urbanic, James J. ;

Sun, Alexander Y. ;

Daly, Megan E. ;

Grills, Inga S. ;

Sperduto, Paul ;

Normolle, Daniel P. ;

Bradley, Jeffrey D. ;

Choy, Hak .

JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15) :1316-+

[9] Salvage Therapy for Locoregional Recurrence After Stereotactic Ablative Radiotherapy for Early-Stage NSCLC [J].

Brooks, Eric D. ;

Verma, Vivek ;

Senan, Suresh ;

De Baere, Thierry ;

Lu, Shun ;

Brunelli, Alessandro ;

Chang, Joe Y. .

JOURNAL OF THORACIC ONCOLOGY, 2020, 15 (02) :176-189

[10] Association of Long-term Outcomes and Survival With Multidisciplinary Salvage Treatment for Local and Regional Recurrence After Stereotactic Ablative Radiotherapy for Early-Stage Lung Cancer [J].

Brooks, Eric D. ;

Sun, Bing ;

Feng, Lei ;

Verma, Vivek ;

Zhao, Lina ;

Gomez, Daniel R. ;

Liao, Zhongxing ;

Jeter, Melenda ;

O'Reilly, Michael ;

Welsh, James W. ;

Quynh-Nhu Nguyen ;

Erasmus, Jeremy J. ;

Eapen, George ;

Ahrar, Kamran ;

Antonoff, Mara B. ;

Hahn, Stephen M. ;

Heymach, John, V ;

Rice, David C. ;

Chang, Joe Y. .

JAMA NETWORK OPEN, 2018, 1 (04)

← 1 2 3 4 5 6 7 →